Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,761.00up ₹3.50 (0.20%)BSE ₹1,762.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,757.50.
29 Oct: open ₹1,757.50, high ₹1,771.50, low ₹1,752.70
52-week range of traded prices to 29 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,22,523 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.93
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.06
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.91%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,07,85459.5% delivered
Sun Pharmaceutical Industries board and management
21 filed, newest first.
Oct 2026
12 Oct · Management
May 2026
12 May · Management
Apr 2026
4 Apr · Management
Jan 2026
31 Jan · Management
Jun 2025
13 Jun · Management
May 2025
6 May · Management
Apr 2024
3 Apr · Management
Mar 2024
29 Mar · Management
Dec 2023
7 Dec · Management
Jan 2023
31 Jan · Management
Nov 2022
Sep 2021
7 Sep · Management
3 Sep · Management
Aug 2021
31 Aug · Management
May 2021
May 2019
Aug 2014
13 Aug · Management
At the Board Meeting of the Company held on August 12, 2014, Mr.Uday Baldota has been appointed as the Chief Financial Officer (CFO) of the Company, as per section 203 of the Companies Act, 2013, with immediate effect.
Feb 2014
13 Feb · Management
Board Of Directors of the Company at its meeting held on February 13, 2014 has appointed Ms. Rekha Sethi as an Additional Independent Director on the Board of Directors of the Company.
May 2012
29 May · Management
Board of Directors of the Company at its meeting held on May 29, 2012 has appointed Mr. Israel Makov, a resident of Israel, as an additional Director on the Board of Directors of the Company. Further, Mr. Dilip Shanghvi has slepped down from the Chairmanship of the Company while continuing to remain the Managing Director of the Company and Mr. Israel Makov has been appointed as the Chairman of the Company at meeting of the Board of Directors of the Company held on May 29, 2012.
Apr 2012
2 Apr · Management
On account of increasing strategic importance of the Group's business interests in North and South America, Mr. Kalyanasundaram Subramanian, now directly responsible for these businesses, shall soon relocate to the USA. Hence, he has resigned as the Director of the Company with effect from March 31, 2012.
Apr 2010
5 Apr · Management
Board of directors of the Company has appointed Shri. Kal Sundaram, as an additional Director on the Board of Directors of the Company and as the Chief Executive Officer of the Company with effect from April 01, 2010.